DMPK Insights

For a captioned and video version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-16-metabolism-studies/#cprtstatus=_cp_0!channel! AAIDoxPJjQQe In this special episode of the Pharmaron DMPK Insights Podcast Series , our experts explore the critical role of metabolism studies in agroche...

For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/ In this episode of the Pharmaron DMPK Insights Podcast Series , Simon Taylor and Dr. Emile Chen​ discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decisio...

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-14-cns-modelling/ In this podcast, Scott Summerfield and Professor Elizabeth de Lange discuss the evolution of CNS drug disposition models , highlighting the increasing sophistication of physiologically based pharmacokinetic ( PBPK ) models, such as LeiCNS-PK3.0. They discuss...

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-13-qsar-physicochemical-descriptors/ In this podcast, Scott Summerfield and Matt Segall will discuss QSAR and how in silico ADME science has evolved to influence Drug Design and improve the ADME properties of hit and lead compounds​. We will address the following questions: ...

For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-12-bbb-transporters/ In this podcast, Elena and Mikko will discuss the current state-of-the-art around transporter sub-types and their expression within the blood-brain barrier (BBB) and opportunities for utilizing these transporters for brain drug delivery.  We will address...

For a captioned version or to access the transcript, please visit https://www.pharmaron.com/knowledge-center/dmpk-podcast-11-gut-microbiome/. In this podcast, Chris Bode (Pharmaron US Labs) interviews Peter Turnbaugh, a microbiologist and Professor of Microbiology and Immunology at the University of California San Francisco. Over the past 15-20 years, Peter has produced so much groundbreaking rese...

In this podcast Simon Taylor (Pharmaron UK) interviews Kevin Beaumont, a highly experienced DMPK scientist, leader and drug developer who has lived and breathed the role of the DMPK Project Representative throughout his 40-year industrial career.  With experience of delivering clinical drug candidates across multiple therapeutic areas with two major pharma companies (Pfizer and AstraZeneca) Kevin...

In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th birthday, Professor Rostami will provide insights into his journey, the dynamic evolution of PBPK and QSP, and the exciting horizons ahead. Tune in for a deep dive into the intersections of academia and industry, technological advan...

In this podcast, Robert MacNeill, Professor Michael Bartlett of the University of Georgia and Dr. Guilherme Guimaraes of Biogen, will focus on oligonucleotide LC-MS covering the exciting key challenges, the pivotal nature of sensitivity in such assays, and the various analytical approaches and technologies that have been used, currently in use or being developed.  The episode explores the followin...

In this podcast, Professor Ian Wilson, a globally recognised and leading expert in drug metabolism, with over 500 publications in the field, takes us on an engaging journey exploring the link between carboxylic acid containing drugs and their involvement in DILI. A special focus will be given to Ian’s latest paper: ‘Minimizing the DILI potential of carboxylic acid-containing drugs: a perspective’....

In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics. The episode explores the following: The impact that mass spectrometry is having in the biotherapeutics and biomarker space The rationale behind the use of LC-MS for certain biomarkers and how sensitive LC-MS assays can be developed (and the practical limits for lower lim...

This podcast format is inspired by the Charles Dicken’s novella “A Christmas Carol” whereby Phil Jeffrey (Bicycle Therapeutics), Beth Williamson (UCB) and Daniel Price (Nimbus) discuss DMPK Past, Present and Future with Scott.  Key elements discussed include the evolution of DMPK as a predictive discipline that links helps the chemistry of drug design with the biology of drug disposition and effec...

In this podcast, Josephine Bunch, Principal Research Scientist and Co-Director of the National Centre of Excellence in Mass Spectrometry (NiCE-MSI) at NPL,  talks about her work, and in particular her involvement in the Cancer Research UK Grand Challenge Programme.   The episode explores the following: Recent innovations in MSI  Challenges associated with analyzing ever more complex molecules Labe...

In this podcast, Scott Summerfield, Senior Director, Pharmaceutical Metabolism at Pharmaron discusses his recent publication on Free Drug Theory (FDT) with Simon including the principles, arguments, and project impact. This article was an invited contribution to a special edition of the Pharmaceutical Research Journal recognizing the achievements of Professor Margareta Hammarlund-Udenaes and Kp,uu...

In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery. The episode addresses the following questions: Why studying biotransformation is an important part of early drug design  A strategy to combine in silico tools, high-resolution MS and software-assisted data analysis to optimize d...

In this podcast, Dr. Paul Morgan, Head of DMPK at Grünenthal Group, discusses the development of the publication that introduced the “5R framework” and improved the likelihood of AstraZeneca candidate survival from candidate drug nomination to Phase III. We will then discuss how the area has developed since then and where the field may go in the future. The episode addresses the following question...